# FDA approves niraparib and abiraterone acetate plus prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer

Source: [What's New: Drugs RSS Feed](http://www.fda.gov/drugs/cancer-approvals/fda-approves-niraparib-and-abiraterone-acetate-plus-prednisone-brca2-mutated-metastatic-castration) · 2026-11-07 · Medicine
Page: https://themorning.science/story/fda-approves-niraparib-and-abiraterone-acetate-plus-prednisone-for-brca2-mutated-307f70fecf5e0204
Kind: launch · Impact: medium

## In brief

- On December 12, 2025, the FDA approved niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.) with prednisone.
- The approval covers adults with deleterious or suspected deleterious BRCA2-mutated metastatic castration-sensitive prostate cancer.

## Why it matters

It adds a targeted combination treatment option for a defined genetic subgroup of metastatic prostate cancer patients, which matters for oncology researchers and clinicians tracking precision-medicine approvals.

## Timeline

- 2025-12-12: FDA approves niraparib and abiraterone acetate with prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer

## Coverage

- [FDA approves niraparib and abiraterone acetate plus prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer](http://www.fda.gov/drugs/cancer-approvals/fda-approves-niraparib-and-abiraterone-acetate-plus-prednisone-brca2-mutated-metastatic-castration) — What's New: Drugs RSS Feed, 2026-11-07

Tags: prostate-cancer, brca2, fda, drug-approval, oncology, precision-medicine

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science